{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T02:01:43Z","timestamp":1771552903920,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-68554-6","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T17:37:01Z","timestamp":1768844221000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM)"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5709-5213","authenticated-orcid":false,"given":"Bo","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3340-4936","authenticated-orcid":false,"given":"Zhen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9122-1535","authenticated-orcid":false,"given":"Xiaohua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danting","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3578-4082","authenticated-orcid":false,"given":"Meiqi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"68554_CR1","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1056\/NEJMe2311559","volume":"389","author":"Y-L Wu","year":"2023","unstructured":"Wu, Y.-L. & Zhou, Q. Combination therapy for EGFR-mutated lung cancer. N. Engl. J. Med. 389, 2005\u20132007 (2023).","journal-title":"N. Engl. J. Med."},{"key":"68554_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11523-021-00794-6","volume":"16","author":"Y Cheng","year":"2021","unstructured":"Cheng, Y. et al. Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study. Target Oncol. 16, 165\u2013176 (2021).","journal-title":"Target Oncol."},{"key":"68554_CR3","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1200\/JCO.21.02641","volume":"40","author":"S Lu","year":"2022","unstructured":"Lu, S. et al. AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon\u2013small-cell Lung cancer with EGFR Exon 19 deletion or L858R mutations. J. Clin. Oncol. 40, 3162\u20133171 (2022).","journal-title":"J. Clin. Oncol."},{"key":"68554_CR4","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2213-2600(20)30455-0","volume":"9","author":"Y Shi","year":"2021","unstructured":"Shi, Y. et al. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study. Lancet Respir. Med. 9, 829\u2013839 (2021).","journal-title":"Lancet Respir. Med."},{"key":"68554_CR5","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/S2213-2600(23)00183-2","volume":"11","author":"S Lu","year":"2023","unstructured":"Lu, S. et al. Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study. Lancet Respir. Med. 11, 905\u2013915 (2023).","journal-title":"Lancet Respir. Med."},{"key":"68554_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"J-C Soria","year":"2018","unstructured":"Soria, J.-C. et al. Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer. N. Engl. J. Med. 378, 113\u2013125 (2018).","journal-title":"N. Engl. J. Med."},{"key":"68554_CR7","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard, D. et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N. Engl. J. Med. 389, 1935\u20131948 (2023).","journal-title":"N. Engl. J. Med."},{"key":"68554_CR8","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","volume":"393","author":"JC-H Yang","year":"2025","unstructured":"Yang, J. C.-H. et al. Overall survival with amivantamab\u2013lazertinib in EGFR-mutated advanced NSCLC. N. Engl. J. Med. 393, 1681\u20131693 (2025).","journal-title":"N. Engl. J. Med."},{"key":"68554_CR9","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","volume":"391","author":"BC Cho","year":"2024","unstructured":"Cho, B. C. et al. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. N. Engl. J. Med. 391, 1486\u20131498 (2024).","journal-title":"N. Engl. J. Med."},{"key":"68554_CR10","doi-asserted-by":"crossref","unstructured":"J\u00e4nne, P. A. et al. Survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC. N. Engl. J. Med. 394, 27\u201339 (2025).","DOI":"10.1056\/NEJMoa2510308"},{"key":"68554_CR11","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.jtho.2020.01.010","volume":"15","author":"Y Shi","year":"2020","unstructured":"Shi, Y. et al. Safety, clinical activity, and pharmacokinetics of alflutinib (AST2818) in patients with advanced NSCLC with EGFR T790M mutation. J. Thorac. Oncol. 15, 1015\u20131026 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"68554_CR12","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","volume":"10","author":"Y Shi","year":"2022","unstructured":"Shi, Y. et al. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study. Lancet Respir. Med. 10, 1019\u20131028 (2022).","journal-title":"Lancet Respir. Med."},{"key":"68554_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107346","volume":"184","author":"R Qi","year":"2023","unstructured":"Qi, R. et al. Efficacy and safety of re-challenging 160 mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: a real-world study. Lung Cancer 184, 107346 (2023).","journal-title":"Lung Cancer"},{"key":"68554_CR14","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","volume":"4","author":"DA Cross","year":"2014","unstructured":"Cross, D. A. et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 4, 1046\u20131061 (2014).","journal-title":"Cancer Discov."},{"key":"68554_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02865-z","volume":"21","author":"X Hu","year":"2023","unstructured":"Hu, X. et al. Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies. BMC Med. 21, 164 (2023).","journal-title":"BMC Med."},{"key":"68554_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10676-x","volume":"23","author":"Z Xu","year":"2023","unstructured":"Xu, Z. et al. Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM\/LM as salvage therapy. BMC Cancer 23, 206 (2023).","journal-title":"BMC Cancer"},{"key":"68554_CR17","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1158\/1078-0432.CCR-22-3146","volume":"29","author":"JE Gray","year":"2023","unstructured":"Gray, J. E. et al. Early clearance of plasma epidermal growth factor receptor mutations as a predictor of outcome on osimertinib in advanced non\u2013small cell lung cancer; exploratory analysis from AURA3 and FLAURA. Clin. Cancer Res. 29, 3340\u20133351 (2023).","journal-title":"Clin. Cancer Res."},{"key":"68554_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam, S. S. et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N. Engl. J. Med. 382, 41\u201350 (2020).","journal-title":"N. Engl. J. Med."},{"key":"68554_CR19","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.jtho.2024.09.027","volume":"19","author":"C Zhou","year":"2024","unstructured":"Zhou, C. & Xiong, A. OA02. 04 A phase III study of rilertinib versus gefitinib as first-line therapy for patients with locally advanced or metastatic EGFR-mutated NSCLC. J. Thorac. Oncol. 19, S11 (2024).","journal-title":"J. Thorac. Oncol."},{"key":"68554_CR20","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1200\/JCO.21.02911","volume":"40","author":"E Miyauchi","year":"2022","unstructured":"Miyauchi, E. et al. Updated analysis of NEJ009: gefitinib-alone versus gefitinib plus chemotherapy for non\u2013small-cell lung cancer with mutated EGFR. J. Clin. Oncol. 40, 3587\u20133592 (2022).","journal-title":"J. Clin. Oncol."},{"key":"68554_CR21","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1016\/j.jtho.2024.09.185","volume":"19","author":"N Valdiviezo","year":"2024","unstructured":"Valdiviezo, N. et al. MA12.04 FLAURA2: impact of tumor burden on outcomes of 1L osimertinib \u00b1 chemotherapy in patients with EGFR-mutated advanced NSCLC. J. Thorac. Oncol. 19, S102 (2024).","journal-title":"J. Thorac. Oncol."},{"key":"68554_CR22","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/S1556-0864(25)00199-6","volume":"20","author":"JCH Yang","year":"2025","unstructured":"Yang, J. C. H. et al. 4O: amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: final overall survival (OS) from the phase III MARIPOSA study. J. Thorac. Oncol. 20, S6\u2013S8 (2025).","journal-title":"J. Thorac. Oncol."},{"key":"68554_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102583","volume":"9","author":"N Valdiviezo","year":"2024","unstructured":"Valdiviezo, N. et al. 4O first-line (1L) osimertinib (osi) \u00b1 platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: FLAURA2 post-progression outcomes. ESMO Open 9, 102583 (2024).","journal-title":"ESMO Open"},{"key":"68554_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11122-8","volume":"23","author":"FM Eliassen","year":"2023","unstructured":"Eliassen, F. M. et al. Importance of endocrine treatment adherence and persistence in breast cancer survivorship: a systematic review. BMC Cancer 23, 625 (2023).","journal-title":"BMC Cancer"},{"key":"68554_CR25","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jtho.2025.02.003","volume":"20","author":"B Han","year":"2025","unstructured":"Han, B. et al. Safety, pharmacokinetics, and efficacy of TY-9591 (Deuterated Osimertinib Derivative) in advanced EGFR-mutated non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion study. J. Thorac. Oncol. 20, 763\u2013774 (2025).","journal-title":"J. Thorac. Oncol."},{"key":"68554_CR26","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1158\/1078-0432.CCR-19-3064","volume":"26","author":"X Li","year":"2020","unstructured":"Li, X. et al. Routine-dose and high-dose icotinib in patients with advanced non\u2013small cell lung cancer harboring EGFR exon 21-L858R mutation: the randomized, phase II, INCREASE trial. Clin. Cancer Res. 26, 3162\u20133171 (2020).","journal-title":"Clin. Cancer Res."},{"key":"68554_CR27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41392-024-02087-6","volume":"9","author":"J Zhong","year":"2024","unstructured":"Zhong, J. et al. Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial. Signal Transduct. Target. Ther. 9, 369 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"68554_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.euo.2023.05.012","volume":"7","author":"E Crupi","year":"2024","unstructured":"Crupi, E. et al. Circulating tumor DNA as a predictive and prognostic biomarker in the perioperative treatment of muscle-invasive bladder cancer: a systematic review. Eur. Urol. Oncol. 7, 44\u201352 (2024).","journal-title":"Eur. Urol. Oncol."},{"key":"68554_CR29","doi-asserted-by":"crossref","unstructured":"Thompson, J. C. et al. Serial monitoring of circulating tumor DNA by next-generation gene sequencing as a biomarker of response and survival in patients with advanced NSCLC receiving pembrolizumab-based therapy. JCO Precis. Oncol. 5, 510\u2013524 (2021).","DOI":"10.1200\/PO.20.00321"},{"key":"68554_CR30","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.cell.2020.09.001","volume":"183","author":"BY Nabet","year":"2020","unstructured":"Nabet, B. Y. et al. Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition. Cell 183, 363\u2013376. e313 (2020).","journal-title":"Cell"},{"key":"68554_CR31","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski, M. A. et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378, 2288\u20132301 (2018).","journal-title":"N. Engl. J. Med."},{"key":"68554_CR32","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","volume":"2","author":"A Passaro","year":"2021","unstructured":"Passaro, A., J\u00e4nne, P. A., Mok, T. & Peters, S. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat. Cancer 2, 377\u2013391 (2021).","journal-title":"Nat. Cancer"},{"key":"68554_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35961-y","volume":"14","author":"J Chmielecki","year":"2023","unstructured":"Chmielecki, J. et al. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nat. Commun. 14, 1070 (2023).","journal-title":"Nat. Commun."},{"key":"68554_CR34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41392-024-01778-4","volume":"9","author":"J Zhang","year":"2024","unstructured":"Zhang, J. et al. Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer. Signal Transduct. Target Ther. 9, 65 (2024).","journal-title":"Signal Transduct. Target Ther."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68554-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68554-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68554-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T01:04:36Z","timestamp":1771549476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68554-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["68554"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-68554-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"X.Z. and X.W. (Xiaoxuan Wang) were employed by Jiangsu Simcere Diagnostics Co., Ltd. All other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1840"}}